Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupDermatologic OncologySarcomasDiseaseKaposi SarcomaSubgroupICD10C46.1MeSHSarcoma, KaposiSequenceChemotherapyChemo-substanceBortezomibDoxorubicin pegylated liposomalEtoposideGemcitabineIpilimumabLenalidomideNivolumabPaclitaxelPembrolizumabPomalidomideVinorelbineChemo-substanceBortezomibDoxorubicin pegylated liposomalEtoposideGemcitabineIpilimumabLenalidomideNivolumabPaclitaxelPembrolizumabPomalidomideVinorelbineChemo-substanceBortezomibDoxorubicin pegylated liposomalEtoposideGemcitabineIpilimumabLenalidomideNivolumabPaclitaxelPembrolizumabPomalidomideVinorelbineChemo-substanceBortezomibDoxorubicin pegylated liposomalEtoposideGemcitabineIpilimumabLenalidomideNivolumabPaclitaxelPembrolizumabPomalidomideVinorelbineNo. Substances12 RadiotherapySupportive therapySupportive substanceAciclovirBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDimetindenGranisetronPyridoxineSupportive substanceAciclovirBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDimetindenGranisetronPyridoxineSupportive substanceAciclovirBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDimetindenGranisetronPyridoxineSupportive substanceAciclovirBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDimetindenGranisetronPyridoxineNo. Substances1234Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseTherapy intentionpalliativeRisksAlopeciaAnemia Hb below 8g/dlAnorexiaArthalgiaCardiotoxicityColitisConstipationDiarrheaDyspneaEdemaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHeadacheHypertensionHyponatremiaHypophysitisHypothyroidismIncrease AminotransferasesIncrease in lipaseInfectionsNephritisNeuropathyNeutropeniaPancreatitisPneumoniaPruritusPyrexiaRashRenal failure!Thrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorBusakhala NWCianfrocca MDelyon JHosseinipour MCNasti GPolizzotto MNPourcher VReid EGZer ADiseaseKaposi-Sarkom, therapiepflichtigKaposi Sarkom, Erstlinie, ECOG 0-2Kaposi Sarkom, HIV-assoziiert, Erstlinie, ECOG 0-2Kaposi Sarkom, HIV-assoziiert, rezidiviert oder therapierefraktär, ECOG 0-3Kaposi Sarkom, HIV-assoziiert, rezidiviert oder therapierefraktär, unter antiretroviraler TherapieKaposi Sarkom, mild-moderat, HIV-assoziiert, ErstlinieKaposi Sarkom, mindestens 1 VortherapieKaposi Sarkom, rezidiviert oder therapierefraktärOriginAssistance Publique-Hopitaux de Paris, Paris, France, ANRS 154 Lenakap TrialCentro di Riferimento Oncologico, Aviano, ItalyDivision of Oncology, Rambam Health Care Campus, HaifaMakerere College of Health Sciences, Kampala, UgandaNational Cancer Institute, Bethesda, USANorthwestern University, Chicago ILUniversite Paris Cite, INSERM U976 HIPI, Paris, FranceUniversity of California, San Diego Moores Cancer Center, AMC-063 trialUniversity of North Carolina School of Medicine, Chapel Hill, A5264/AMC-067 trialProtocols in Revision 10 protocols foundProtocols under revision.Bortezomib 1.6, Kaposi's Sarcoma (PID2028)Etoposide 50, Kaposi's Sarcoma (PID2032)Gemcitabine 1000, Kaposi's Sarcoma (PID2033)Lenalidomide 25, Kaposi's Sarcoma (PID2029)Nivolumab 240 / Ipilimumab 1, Kaposi Sarcoma (PID2160)Paclitaxel 100, Kaposi Sarcoma (PID1202)Doxorubicin Pegylated Liposomal 20, Kaposi Sarcoma (PID1201)Pembrolizumab 200, Kaposi Sarcoma (PID2592)Pomalidomide 4, Kaposi's Sarcoma (PID2030)Vinorelbine 30, Kaposi's Sarcoma (PID2031)
